Crison
Investors Count
1Funding, Valuation & Revenue
1 Fundings
Crison's latest funding round was a Incubator/Accelerator for on .
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
Incubator/Accelerator |
Date | |
|---|---|
Round | Incubator/Accelerator |
Amount | |
Investors | |
Valuation | |
Revenue | |
Sources |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Crison Investors
1 Investors
Crison has 1 investors. Chicago Technology Park invested in Crison's Incubator/Accelerator funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
1 Incubator/Accelerator | Incubator/Accelerator | Illinois |
First funding | |
|---|---|
Last Funding | |
Investor | |
Rounds | 1 Incubator/Accelerator |
Board Seats | |
Type | Incubator/Accelerator |
Location | Illinois |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Crison to Competitors
ERA Biotech is a company focused on biotechnology. The company offers a range of technologies for protein engineering, gene therapy, and vaccine development. These technologies include tools for tag-less protein purification, antibody bioconjugation, protein modification, and the creation of nucleic acid and recombinant vaccines. It was founded in 2002 and is based in Spain.
greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins
Elevation Biotech specialises in the design and discovery of small peptide and peptidomimetic HIV attachment inhibitors. The company have developed biochemical and virological in vitro assays that screen specifically for the ability of compounds to block or interfere with viral attachment to the cell surface receptor CD4. The company's lead compound, is a short 7 amino acid peptide that binds to HIV envelope protein gp120 thereby preventing attachment of virus to the CD4 molecule.
Biolog is a company that specializes in microbial identification and characterization, operating within the biotechnology industry. The company offers products and services that enable the characterization of microbial and mammalian cells, as well as the identification of a wide range of bacteria, yeast, and fungi. Biolog primarily serves sectors such as bioprocess and fermentation, environmental monitoring and quality control, brewing, probiotics, drug discovery and diagnostics, and basic research. It was founded in 1984 and is based in Hayward, California.
Oligomerix is a biotechnology company that focuses on the development of disease-modifying therapeutics for neurodegenerative diseases, specifically those characterized by aberrant tau protein. The company's main offerings include small molecule inhibitors that target the tau aggregation cascade and its progression, aiming to treat conditions ranging from rare tauopathies to Alzheimer's disease. The company primarily serves the healthcare sector, particularly in the area of neurodegenerative diseases. It was founded in 2006 and is based in West Harrison, New York.
MI Research, Inc. specializes in Biotech instrumentation with excellent visualization capabilities in the area of protein crystal growth and blood viscosity measurements. MI aims to offer fluorescence base protein crystallization prescreening service and biotech instruments like blood viscometers. MI's expertise is in optics and biochemistry.
Loading...